Detailseite
Projekt Druckansicht

Analyse der molekularen Pathomechanismen der GBA1 assoziierten Parkinson Krankheit in genomisch veränderten, induzierten pluripotenten Stammzellen

Antragstellerin Michela Deleidi, Ph.D.
Fachliche Zuordnung Molekulare und zelluläre Neurologie und Neuropathologie
Förderung Förderung von 2014 bis 2019
Projektkennung Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 264574831
 
Erstellungsjahr 2019

Zusammenfassung der Projektergebnisse

Parkinson's is the second most common movement disorder that affects around two percent of people over 60 worldwide, and the numbers are rising. Typical symptoms include motor impairments such as unsteady hands, stiff muscles and slow movements. The disease is caused by the loss of dopamine-containing nerve cells in a certain brain region called substantia nigra. There is no effective treatment for this disease to date. Little is known about the causes of the disease. Mitochondrial damage is a key feature in Parkinson's disease. Dopamine neurons, the neurons that are selectively affected in Parkinson's, are particularly susceptible to energy failure. It is not known whether increasing the formation of new young mitochondria and their function is protective in Parkinson's disease. We have found that common gene mutations linked to Parkinson's disease, namely mutations in a gene called GBA, lead to defects in mitochondrial function and the metabolism of nicotinamide adenine dinucleotide (NAD+), which is an essential molecule found in every living cell. Specifically, we show mitochondrial changes in human neurons from Parkinson's disease patients and we demonstrate that the supplementation with a form of vitamin B, nicotinamide riboside, boosts mitochondrial formation and function in Parkinson's disease patient stem cell-derived neurons and it is neuroprotective in Parkinson's disease animal models. Importantly, recent studies have shown that the supplementation with nicotinamide riboside is well tolerated in healthy subjects and efficiently raises NAD+ levels. Thus, we propose that nicotinamide riboside could be a safe and efficacious therapeutic approach in Parkinson's disease patients. https://www.gesundheitsindustrie-bw.de/en/article/news/parkinsons-disease-vitamin-b3-has-a-positive-effect-on-nerve-cells https://uni-tuebingen.de/universitaet/aktuelles-und-publikationen/pressemitteilungen/newsfullview-pressemitteilungen/article/parkinsonvitamin-b3-hat-positive-wirkung-auf-geschaedigte-nervenzellen/

Projektbezogene Publikationen (Auswahl)

 
 

Zusatzinformationen

Textvergrößerung und Kontrastanpassung